Drugs

Public Notification: B-Lipo contains a hidden drug ingredient

[12-23-2014] The Food and Drug Administration (FDA) is advising consumers not to purchase or use B-Lipo, a product promoted and sold for weight loss on various websites, including www.bethel30.com, and in some retail stores.Image of B-Lipo

FDA laboratory analysis confirmed that B-Lipo contains lorcaserin, a controlled substance and the active ingredient in the FDA-approved prescription drug Belviq®, used for chronic weight management in some overweight or obese adults.  Lorcaserin may cause psychiatric disturbances and impairments in attention or memory. Also, concomitant use of lorsaserin with certain medications, such as, but not limited to, drugs commonly used to treat depression and migraine, may result in a potentially life-threatening drug interaction.
 
Bethel Nutritional Consulting, Inc., has issued a press release voluntarily recalling B-Lipo capsules.
 
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of this product to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
 
Note: This notification is to inform the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals. These products are typically promoted for sexual enhancement, weight loss, and body building and are often represented as being “all natural.” FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. Consumers should exercise caution before purchasing any product in the above categories. 
 
Please refer to the links below for more information:
 
 
 

 

Contact FDA

Toll Free
(855) 543-3784, or
(301) 796-3400
Human Drug Information

Division of Drug Information (CDER)

Office of Communications

Feedback Form

10001 New Hampshire Avenue

Hillandale Building, 4th Floor

Silver Spring, MD 20993

Page Last Updated: 12/23/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English